Cerebral amyloid angiopathy is diagnosed in stroke units after lobar intracerebral hemorrhage. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Research
28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
In recent years, studies have demonstrated that hypertension-related changes (e.g., small vascular lesions, inflammatory reactions, hypoperfusion, oxidative stress, damage to autoregulatory processes and the blood-brain barrier, and cerebral amyloid angiopathy) can occur over time in cerebral small vessels, potentially leading to lower cognitive function when blood pressure (BP) control is poor or lacking. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Androgens affect the cerebral vasculature and may contribute to sex differences in cerebrovascular diseases. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
The prevalence of BMB is highly variable (3%-27% in the general population, 6%-80% in patients with vascular risk factors or vascular disease, and 16%-45% in patients with cognitive impairment). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
39/100
Dozens of genes have been implicated in late onset Alzheimer's disease (AD) risk, but none has a defined mechanism of action in neurons. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The endosomal-lysosomal pathways and related autophagic processes are responsible for proteostasis, involving complexes between lysosomes and autophagosomes. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Traumatic brain injury (TBI) is a major health and economic burden. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
EEG characteristics that correlate with the cognitive functions are important in detecting mild cognitive impairment (MCI) in T2DM. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
It has been clearly established that there is an increased incidence of early onset dementia of the Alzheimer type (DAT) in people who have Down syndrome. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Diabetes care guidelines recommend more relaxed glycemic targets for patients with specific chronic conditions because they are thought to have an increased risk of hypoglycemia, limited life expectancy, and/or high clinical complexity. 3 key findings →
Participants: 216,839 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The burden of dementia will continue to rise globally, particularly in developing countries, many of which lie in the Asia-Pacific region. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Patients (N = 2,512) receiving lecanemab infusion had a mean age of 75.4 (standard deviation = 5.7) years as compared to 80.8 (8.9) years in patients with MCI/AD not receiving the infusion. 5 key findings →
Participants: 2,512 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Diagnostic classifications, mean age, and education did not differ significantly across classifications. 5 key findings →
Design: cross-sectional Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
There is a consistent difference between Appalachian and non‐Appalachian counties, with Appalachian counties having relatively higher ADRD prevalence (in the range of 2.0‐3.0% times higher) than non‐Appalachian counties. 4 key findings →
Participants: 255 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
In a national database of Medicare claims, there were substantial secular trends and differences in coding of dementia subtypes by race/ethnicity, sex, and neighborhood socioeconomic status. 2 key findings →
Participants: 100 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Accidental femur fractures in older adults are a public health concern with a considerably high rate of mortality and morbidity. 2 key findings →
Participants: 312 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The AD PRS was associated with AD in the ADSP sample, with odds ratios per standard deviation ranging from 1.14 to 1.52 across ancestry groups and robust validation in independent cohorts (Figure 1). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Cardiovascular diseases (CVDs) remain the main cause of mortality and are generally among the leading causes of morbidity worldwide, thus placing an immense burden on health care. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Of 81 stroke survivors (mean age 61.9±13.9 years), 72.8% had ischemic stroke, and 27.2% had hemorrhagic stroke. 5 key findings →
Design: cross-sectional Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
average annual dementia incidence in White, but not Black, adults (1% versus 0%), due to hypertensive individuals' greater survival, and reduce annual ASCVD events more in Black than White adults (13% versus 5%). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Between 1990 and 2021, ADOD incidence, prevalence, deaths, and DALYs increased significantly. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
38/100
The incidence of dementia, and specifically, Alzheimer's disease, is higher in women than men, even in middle age, making it possible to rule out lifespan differences between men and women as a contributing factor. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer?s disease (AD) is a neurodegenerative disorder with a strong genetic component. 4 key findings →
Design: case-control study Participants: 98 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Dementia incidence was 0.89 per 1000 person-years. 5 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
38/100
Traumatic brain injury (TBI) is one of the main mechanisms underlying health issues associated with functional and structural brain changes. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
From across this tag
10 of the 3,281 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Relation of obesity to cognitive function: importance of central obesity and synergistic influence of concomitant hypertension. The Framingham Heart Study
- Association Between Birth in a High Stroke Mortality State, Race, and Risk of Dementia
- Cancer linked to Alzheimer disease but not vascular dementia
- Readily Identifiable Risk Factors of Nursing Home Residents' Oral Hygiene: Dementia, Hospice, and Length of Stay
- Statistical methods for dementia risk prediction and recommendations for future work: A systematic review
- Physical activity, falls, and dementia risk in adults aged ≥ 60: evidence from three cohorts
- Gender difference in apolipoprotein E-associated risk for familial Alzheimer disease: a possible clue to the higher incidence of Alzheimer disease in women
- Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort
- Modifiable Lifestyle Risk Factors and Strategies for Slowing the Progression of Age-Related Macular Degeneration
- Metabolically healthy obesity and risk of leukoaraiosis; a population based cross-sectional study
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →